Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.DMRA · Entity 4602 | General Counsel | July 03, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date July 03, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,289 |
Ending reported balance
After 2026-07-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-03 · Exercise / conversion · Acquired 680 · Balance 2,534 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Row 2 · 2026-07-06 · Sale · Disposed 245 · Balance 2,289 F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 640 |
Reported balance
After 2026-07-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-03 · Exercise / conversion · Disposed 680 · Balance 640 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
F-star Therapeutics, Inc.
Report date November 19, 2020 · Filed November 23, 2020
Section 16 reporting ended · disclosed 2020-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,575 |
Ending reported balance
After 2020-11-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-11-19 · Exercise / conversion · Acquired 6,250 · Balance 6,250 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Row 2 · 2020-11-19 · Grant · Acquired 12,500 · Balance 18,750 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Row 3 · 2020-11-20 · Sale · Disposed 175 · Balance 18,575 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-19 · Exercise / conversion · Disposed 6,250 · Balance 0 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F2: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis.
F2: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 00:00 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | SaleCommon Stock | 245 | $29.98 | $7,345.10 |
DisclosureSEC source: 0001193125-26-297818 · ownership.xml · nonDerivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,289 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 03, 2026 Filed Jul 8, 2026 00:00 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-297818 · ownership.xml · derivative · entry 3 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| July 03, 2026 Filed Jul 8, 2026 00:00 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-297818 · ownership.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 22:09 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001193125-26-124487 · ownership.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-03-23 F1 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 23, 2027 and in equal monthly installments thereafter through March 23, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004568 · ownership.xml · derivative · entry 3 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,320 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 255 | $21.38 | $5,451.90 |
DisclosureSEC source: 0001193125-26-004568 · ownership.xml · nonDerivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,854 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-004568 · ownership.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094575 · ownership.xml · derivative · entry 3 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 260 | $3.39 | $881.40 |
DisclosureSEC source: 0000950170-25-094575 · ownership.xml · nonDerivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094575 · ownership.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000950170-25-002814 · ownership.xml · derivative · entry 4 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2035-01-03 F4 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 1,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002814 · ownership.xml · derivative · entry 3 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,680 Underlying: Common Stock · 1,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 471 | $5.60 | $2,637.60 |
DisclosureSEC source: 0000950170-25-002814 · ownership.xml · nonDerivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,009 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 1,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002814 · ownership.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 15,600 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000950170-24-114387 · ownership.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2034-10-09 F1 · derivative.exercise_date: The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002429 · ownership.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001209191-23-001758 · doc4.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-002213 · doc4.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 13:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 2,000 | $2.48 | $4,960.00 |
DisclosureSEC source: 0001209191-21-068028 · doc4.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| June 23, 2021 Filed Jun 23, 2021 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 2,000 | $4.80 | $9,600.00 |
DisclosureSEC source: 0001209191-21-042718 · doc4.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $5.61 | $0.00 |
DisclosureSEC source: 0001209191-21-040944 · doc4.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on May 2, 2022 and the remainder of the shares will vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 16:14 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | SaleCommon Stock | 175 | $4.76 | $833.00 |
DisclosureSEC source: 0000905718-20-001132 · springbank_fm4nov192020.xml · nonDerivative · entry 3 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,575 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:14 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-001132 · springbank_fm4nov192020.xml · derivative · entry 4 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F2 · derivative.exercise_date: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. F2 · derivative.expiration_date: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:14 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-001132 · springbank_fm4nov192020.xml · nonDerivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:14 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-001132 · springbank_fm4nov192020.xml · nonDerivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:15 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017242 · doc4.xml · derivative · entry 2 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021. F3 · derivative.expiration_date: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:15 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-20-017242 · doc4.xml · derivative · entry 1 Winslow Garrett · CIK 0001803773 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.